ISIN:DE0006632003

EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

Retrieved on: 
Mittwoch, April 10, 2024
MorphoSys, Takeover, Acquisition, HSR

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the proposed acquisition of MorphoSys by Novartis AG (“Novartis”), following the expiration of the HSR Act waiting period.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the proposed acquisition of MorphoSys by Novartis AG (“Novartis”), following the expiration of the HSR Act waiting period.
  • MorphoSys previously also announced the receipt of antitrust clearance in Germany and Austria.
  • As a result, the proposed acquisition of MorphoSys by Novartis has now received all mandatory regulatory approvals.
  • MorphoSys and Novartis continue to expect the closing of the Takeover Offer to take place in the first half of 2024.

EQS-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal 2023 und das Geschäftsjahr 2023 und informiert über die aktuelle Unternehmensentwicklung

Retrieved on: 
Mittwoch, April 10, 2024
Ausgabe, Material, Website, Unternehmen, Englische Sprache, Deutsch, Post, Morphosys, Planegg, Aussage, Politische Partei, Bedingung, Vollzug, Zeitmanagement, Ziel, Erwartung, Absicht, Ertragskraft, Novartis, Risiko, Ungewissheit, Ergebnis, Unsicherheit, Zeitpunkte, Anzahl, Aktie, Rahmen, Angebot, Stelle, Genehmigung, Wirkung, Beziehung, Arbeitnehmer, Vorteil, Transaktionskosten, Zusammenhang, Studie, Kooperation, Potential, Risikofaktor, Unterlagen, Geschäftsbericht, Form, Schedule, Tender, Offer, Statement, Verpflichtetsein, Bezug, Ereignis, Wahrscheinlichkeit, Constellation, DAS

EQS-News: MorphoSys gibt US-Kartellfreigabe der geplanten Übernahme durch Novartis gemäß HSR Act bekannt

Retrieved on: 
Mittwoch, April 10, 2024
Zusammenhang, Novartis, Tender, Offer, Statement, Schedule, Purchase, Dokument, Unterlagen, Ausgabe, Material, Website, Unternehmen, Englische Sprache, Deutsch, Post, Morphosys, Planegg, Aussage, Risiko, Unsicherheit, Politische Partei, Bedingung, Vollzug, Zeitmanagement, Ziel, Erwartung, Absicht, Ertragskraft, Ungewissheit, Ergebnis, Zeitpunkte, Anzahl, Aktie, Rahmen, Angebot, Stelle, Genehmigung, Wirkung, Beziehung, Arbeitnehmer, Vorteil, Transaktionskosten, Studie, Kooperation, Potential, Risikofaktor, Geschäftsbericht, Form, DAS

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Mittwoch, April 10, 2024
Novartis, ASH, Tafasitamab, Webcast, Purchasing, EZH1, EDT, Acquisition, Standard of care, BET, Business analyst, EZH2, Ruxolitinib, Exposition, Society, Safety, Anemia, GMT, MorphoSys, JAK, Annual general meeting, Pharmaceutical industry

“Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.

Key Points: 
  • “Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.
  • With its ample resources, additional scientific expertise and global footprint, Novartis can help accelerate pelabresib's potential worldwide.
  • Total revenues for the fourth quarter 2023 were € 59.0 million compared to € 81.6 million for the same period in 2022.
  • The decrease resulted first and foremost from prior year revenues stemming from the execution of an out-licensing agreement with Novartis.

EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024

Retrieved on: 
Mittwoch, März 13, 2024
EDT, MorphoSys, GMT, Management, Q&A, Webcast, Conference

Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024

Key Points: 
  • Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
  • MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.

EQS-News: Einladung zu MorphoSys' Telefonkonferenz am 14. März 2024 zu den Ergebnissen des Geschäftsjahres 2023

Retrieved on: 
Mittwoch, März 13, 2024
Aussage, Unternehmen, Politische Partei, Bedingung, Vollzug, Zeitmanagement, Ziel, Erwartung, Absicht, Ertragskraft, Novartis, Zeitpunkt, Risiko, Ungewissheit, Ergebnis, Leistung, Errungenschaft, Ausdruck, Unsicherheit, Zeitpunkte, Anzahl, Aktie, Rahmen, Angebot, Stelle, Genehmigung, Wirkung, Beziehung, Arbeitnehmer, Vorteil, Transaktionskosten, Zusammenhang, Studie, Kooperation, Potential, Risikofaktor, Unterlagen, Geschäftsbericht, Form, Schedule, Tender, Offer, Statement, Verpflichtetsein, Bezug, Ereignis, Wahrscheinlichkeit

EQS-News: MorphoSys schließt Vereinbarung zur Übernahme durch Novartis für Eigenkapitalwert von € 2,7 Milliarden

Retrieved on: 
Dienstag, Februar 6, 2024
Novartis, Ressource, Umfang, Doktor, Morphosys, Incyte, Information, Zusammenhang, Genehmigung, Bundesanstalt für Finanzdienstleistungsaufsicht, Website, Ausgabe, Material, Unternehmen, Englische Sprache, Deutsch, Post, Planegg, Aussage, Politische Partei, Bedingung, Vollzug, Zeitmanagement, Ziel, Erwartung, Absicht, Ertragskraft, Risiko, Ungewissheit, Ergebnis, Unsicherheit, Zeitpunkte, Anzahl, Aktie, Rahmen, Angebot, Stelle, Wirkung, Beziehung, Arbeitnehmer, Vorteil, Transaktionskosten, Studie, Kooperation, Potential, Risikofaktor, Unterlagen, Geschäftsbericht, Form, Schedule, Tender, Offer, Statement, Slate, Constellation, DAS

EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Retrieved on: 
Dienstag, Februar 6, 2024
Slate, Partnership, Supervisory board, Centerview Partners, Immediate, Novartis, Tender offer, Tafasitamab, Purchasing, EZH2, Ruxolitinib, Patient, BET, Workforce, GMT, EZH1, Federal Financial Supervisory Authority, Disease, Acquisition, AG, EST, Business analyst, Webcast, Cancer, Schedule, Pharmaceutical industry

Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).

Key Points: 
  • Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).
  • “Novartis shares our steadfast commitment to develop and deliver transformative medicines that address the dire needs of cancer patients.
  • Novartis intends to offer MorphoSys’ shareholders € 68.00 per share in cash, for a total equity value of € 2.7 billion.
  • Creates New Opportunities for MorphoSys’ Colleagues: The agreement between Novartis and MorphoSys includes employee commitments.

EQS-News: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Retrieved on: 
Dienstag, Januar 30, 2024
European Medicines Agency, B-cell lymphoma, Food, Growth

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Key Points: 
  • MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
    Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69%
    Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 114 million, representing a reduction of € 112 million
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) today reported preliminary Monjuvi® (tafasitamab-cxix) U.S. net product sales and gross margin for Monjuvi U.S. net product sales for the full year of 2023 and provides its 2024 financial guidance.
  • For the full year of 2024, MorphoSys expects Monjuvi U.S. net product sales in the range of US$ 80 to 95 million, aligned with the company’s original 2023 guidance.
  • Further, preliminary 2023 gross margin for Monjuvi U.S. net product sales is 69%, which is impacted by the recognition of one-time write-offs for inventory.

EQS-News: MorphoSys gibt vorläufigen Monjuvi-Umsatz und Bruttomarge für 2023 bekannt, veröffentlicht Finanzprognose für 2024 und reduziert finanzielle Verbindlichkeit

Retrieved on: 
Dienstag, Januar 30, 2024
Morphosys, Tantieme, Material, Partner, Incyte, Prognose, U.S., Administration, Kombination, Lenalidomid, Behandlung, Patient, Diffuses großzelliges B-Zell-Lymphom, DLBCL, Lymphom, Stammzelltransplantation, Frage, Zulassung, Indikation, Beschreibung, Nutzen, Studie, Aussage, Zeitpunkt, Risiko, Unsicherheit, Ergebnis, Leistung, Erfolg, Branche, Ausdruck, Entwicklung, Unternehmen, Faktor, Abweichung, Tatsache, Erwartung, Ungewissheit, Zusammenhang, Kooperation, Potential, Risikofaktor, Geschäftsbericht, Formular, Unterlagen, Verpflichtetsein, Dokument, Bezug, Ereignis, Bedingung, Wahrscheinlichkeit, Constellation, Treffen